A Study of Baricitinib and Rifampicin in Healthy Participants

NCT01910311 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Baricitinib
DRUG: Rifampicin

Sponsor

Eli Lilly and Company